Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bruce Booth sold 467,878 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the completion of the sale, the director directly owned 472,267 shares of the company's stock, valued at $52,086,327.43. The trade was a 49.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bruce Booth also recently made the following trade(s):
- On Monday, June 29th, Bruce Booth sold 45,367 shares of Kymera Therapeutics stock. The stock was sold at an average price of $107.06, for a total value of $4,856,991.02.
- On Monday, June 29th, Bruce Booth sold 31,283 shares of Kymera Therapeutics stock. The stock was sold at an average price of $109.48, for a total value of $3,424,862.84.
- On Thursday, June 25th, Bruce Booth sold 285,684 shares of Kymera Therapeutics stock. The shares were sold at an average price of $121.86, for a total value of $34,813,452.24.
- On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The shares were sold at an average price of $115.39, for a total value of $30,305,683.43.
- On Wednesday, June 24th, Bruce Booth sold 134,720 shares of Kymera Therapeutics stock. The shares were sold at an average price of $100.51, for a total transaction of $13,540,707.20.
- On Tuesday, June 23rd, Bruce Booth sold 1,408 shares of Kymera Therapeutics stock. The stock was sold at an average price of $99.98, for a total transaction of $140,771.84.
- On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The stock was sold at an average price of $98.52, for a total transaction of $24,268,431.60.
- On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.01, for a total transaction of $10,471,246.56.
- On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.38, for a total transaction of $9,496,316.98.
- On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total transaction of $1,056,455.18.
Kymera Therapeutics Stock Up 4.9%
Shares of KYMR opened at $114.67 on Wednesday. The firm has a market cap of $9.43 billion, a PE ratio of -32.12 and a beta of 2.02. The company's fifty day moving average is $85.81 and its two-hundred day moving average is $82.55. Kymera Therapeutics, Inc. has a fifty-two week low of $36.65 and a fifty-two week high of $130.05.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. The company had revenue of $34.37 million during the quarter, compared to analysts' expectations of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business's quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.82) EPS. As a group, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current year.
Institutional Investors Weigh In On Kymera Therapeutics
Several hedge funds have recently modified their holdings of KYMR. Empowered Funds LLC acquired a new position in Kymera Therapeutics during the 1st quarter worth approximately $203,000. Glenmede Trust Co. NA grew its position in Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company's stock valued at $565,000 after acquiring an additional 235 shares in the last quarter. Amundi purchased a new stake in shares of Kymera Therapeutics during the first quarter valued at approximately $249,000. California State Teachers Retirement System raised its stake in shares of Kymera Therapeutics by 23.0% during the first quarter. California State Teachers Retirement System now owns 56,282 shares of the company's stock valued at $4,688,000 after purchasing an additional 10,540 shares during the period. Finally, Eagle Health Investments LP lifted its position in shares of Kymera Therapeutics by 7.0% during the first quarter. Eagle Health Investments LP now owns 145,816 shares of the company's stock worth $12,145,000 after purchasing an additional 9,516 shares in the last quarter.
Analysts Set New Price Targets
Several equities research analysts have commented on the company. Bank of America upped their price target on Kymera Therapeutics from $110.00 to $125.00 and gave the stock a "buy" rating in a research note on Tuesday. Brookline Capital Markets reaffirmed a "buy" rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Truist Financial increased their target price on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a "buy" rating in a research report on Monday. B. Riley Financial raised their price target on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the company a "buy" rating in a report on Monday. Finally, Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $121.41.
View Our Latest Analysis on KYMR
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
